MRVI Maravai LifeSciences Holdings

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at .

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.



Contact Information:
Deb Hart
Maravai LifeSciences
 7
EN
01/05/2025

Underlying

MRVIMaravai LifeSciences Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Maravai LifeSciences Holdings

 PRESS RELEASE
Free
MRVI Maravai LifeSci...

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer a...

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating innovation, execut...

June 9, 2025 1 EN
 PRESS RELEASE
Free
MRVI Maravai LifeSci...

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the ...

May 21, 2025 1 EN
 PRESS RELEASE
Free
MRVI Maravai LifeSci...

Maravai LifeSciencesReleases 2024 Sustainability Report

Maravai LifeSciencesReleases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech ...

May 21, 2025 1 EN
 PRESS RELEASE
Free
MRVI Maravai LifeSci...

Maravai Lifesciences Reports First Quarter 2025 Financial Results

Maravai Lifesciences Reports First Quarter 2025 Financial Results SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full y...

May 12, 2025 1 EN
 PRESS RELEASE
Free
MRVI Maravai LifeSci...

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 1...

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025 SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference I...

May 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch